Tags

Type your tag names separated by a space and hit enter

[Cytomegalovirus diseases after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) and related risk factors].
Zhonghua Yi Xue Za Zhi. 2003 May 10; 83(9):766-9.ZY

Abstract

OBJECTIVE

To analyze the incidence of cytomegalovirus (CMV) diseases after allogeneic hematopoietic stem cell transplantation (allo-HSCT) and related risk factors.

METHODS

The clinical data of 131 patients undergoing allo-HSCT August 1999 to July 2001 were analyzed retrospectively.

RESULTS

Twenty-eight of the 131 patients developed CMV interstitial pneumonia (IP) with an incidence rate of 21.35%, 9 patients developed CMV enteritis with an incidence rate of 6.87%; in total 37 of the 131 patients developed CMV disease with the accumulative one-year incidence rate of 32.54%. Thirteen patients (35.14%)died of CMV diseases. Univariate analysis showed that accumulative incidence of CMV disease was associated with unrelated donor, II-IV degrees acute graft versus host disease (aGVHD), additional immunosuppressive therapy for GVHD, chronic graft versus host disease (cGVHD), antilymphocyte globulin (ALG)/monoclonal antibody (MoAb) administration, high dose of methylprednisolone (MP), plasma viramia-PCR (PV-PCR) positivity of patients, blood transfusion and pre-emptive treatment. Multivariate analysis showed that risk factors for CMV disease included plasma CMV-DNA positivity, immense amount of blood transfused, and additional immunosuppressive therapy for aGVHD, and pre-emptive therapy capable of turning PV-PCR positive reduced the incidence of CMV disease (RR: 3.309, 1.046, 2.242, and 0.346).

CONCLUSION

CMV disease has a high morbidity and mortality in allo-HSCT patients. Patients with positive plasma CMV-DNA should receive pre-emptive therapy till their plasma CMV-DNA turns to be negative, especially in condition of severe aGVHD, immense amount of blood transfused, or additional immunosuppressive therapy.

Authors+Show Affiliations

Institute of Hematology, People's Hospital, Peking University, Beijing 100044, China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article

Language

chi

PubMed ID

12899755

Citation

Huang, Xiao-jun, et al. "[Cytomegalovirus Diseases After Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) and Related Risk Factors]." Zhonghua Yi Xue Za Zhi, vol. 83, no. 9, 2003, pp. 766-9.
Huang XJ, Xu LP, Ren HY, et al. [Cytomegalovirus diseases after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) and related risk factors]. Zhonghua Yi Xue Za Zhi. 2003;83(9):766-9.
Huang, X. J., Xu, L. P., Ren, H. Y., Zhang, Y. C., Guo, N. L., & Lu, D. P. (2003). [Cytomegalovirus diseases after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) and related risk factors]. Zhonghua Yi Xue Za Zhi, 83(9), 766-9.
Huang XJ, et al. [Cytomegalovirus Diseases After Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) and Related Risk Factors]. Zhonghua Yi Xue Za Zhi. 2003 May 10;83(9):766-9. PubMed PMID: 12899755.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Cytomegalovirus diseases after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) and related risk factors]. AU - Huang,Xiao-jun, AU - Xu,Lan-ping, AU - Ren,Han-yun, AU - Zhang,Yao-chen, AU - Guo,Nai-lan, AU - Lu,Dao-pei, PY - 2003/8/6/pubmed PY - 2004/9/15/medline PY - 2003/8/6/entrez SP - 766 EP - 9 JF - Zhonghua yi xue za zhi JO - Zhonghua Yi Xue Za Zhi VL - 83 IS - 9 N2 - OBJECTIVE: To analyze the incidence of cytomegalovirus (CMV) diseases after allogeneic hematopoietic stem cell transplantation (allo-HSCT) and related risk factors. METHODS: The clinical data of 131 patients undergoing allo-HSCT August 1999 to July 2001 were analyzed retrospectively. RESULTS: Twenty-eight of the 131 patients developed CMV interstitial pneumonia (IP) with an incidence rate of 21.35%, 9 patients developed CMV enteritis with an incidence rate of 6.87%; in total 37 of the 131 patients developed CMV disease with the accumulative one-year incidence rate of 32.54%. Thirteen patients (35.14%)died of CMV diseases. Univariate analysis showed that accumulative incidence of CMV disease was associated with unrelated donor, II-IV degrees acute graft versus host disease (aGVHD), additional immunosuppressive therapy for GVHD, chronic graft versus host disease (cGVHD), antilymphocyte globulin (ALG)/monoclonal antibody (MoAb) administration, high dose of methylprednisolone (MP), plasma viramia-PCR (PV-PCR) positivity of patients, blood transfusion and pre-emptive treatment. Multivariate analysis showed that risk factors for CMV disease included plasma CMV-DNA positivity, immense amount of blood transfused, and additional immunosuppressive therapy for aGVHD, and pre-emptive therapy capable of turning PV-PCR positive reduced the incidence of CMV disease (RR: 3.309, 1.046, 2.242, and 0.346). CONCLUSION: CMV disease has a high morbidity and mortality in allo-HSCT patients. Patients with positive plasma CMV-DNA should receive pre-emptive therapy till their plasma CMV-DNA turns to be negative, especially in condition of severe aGVHD, immense amount of blood transfused, or additional immunosuppressive therapy. SN - 0376-2491 UR - https://www.unboundmedicine.com/medline/citation/12899755/[Cytomegalovirus_diseases_after_allogeneic_hematopoietic_stem_cell_transplantation__Allo_HSCT__and_related_risk_factors]_ L2 - http://journal.yiigle.com/LinkIn.do?linkin_type=pubmed&issn=0376-2491&year=2003&vol=83&issue=9&fpage=766 DB - PRIME DP - Unbound Medicine ER -